A study to evaluate the pharmacokinetics, safety and tolerability after inhalation of MMI-0100 in healthy subjects; MMI-0100 is an investigational drug developed for the treatment of fibrotic indications. - MMI-0100 SAD study.

Moerae Matrix, Inc0 sites48 target enrollmentTBD

Conditionsidiopathische fibrose Idiopathic pulmonary fibrosis pulmonary diseases.

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: idiopathische fibrose
Sponsor: Moerae Matrix, Inc
Enrollment: 48
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Similar Trials

Overview

Brief Summary

No summary available.

Registry

who.int

Start Date

TBD

End Date

TBD

Last Updated

2 years ago

Study Type

Interventional

Investigators

Sponsor

Moerae Matrix, Inc

Eligibility Criteria

Inclusion Criteria

•Healthy male or female
•18 and 55 years of age, inclusive
•BMI 19\.0 and 30\.0 kilograms/meter2
•Non smokers

Exclusion Criteria

•Suffering from hepatitis B, hepatitis C, cancer or HIV/AIDS. In case of participation in another drug study within 90 days before the start of this study or being a blood donor within 60 days from the start of the study. In case of donating more than 1\.5 liters of blood in the 10 months prior to the start of this study.

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed

Not Applicable

A study evaluating the pharmacokinetics, safety and tolerability of OP2113 administered intravenously in healthy volunteers and a marketed formulation administered orally

NL-OMON48072OP2 Drugs12

Completed

Not Applicable

The aim of this study is to compare and evaluate the pharmacokinetic properties and safety of oral administration of test drugEndocrine, nutritional and metabolic diseases

KCT0004026Kyung Dong Pharmaceutical80

Active, not recruiting

Not Applicable

Study to evaluate the safety and pharmacokinetics of ciprofloxacin following inhalation of ciprofloxacin dry powder for inhalation administered to pediatric patients with cystic fibrosis aged 12-17 yearslong term treatment of chronic lung infections caused by Pseudomonas aeruginosa in patients with cystic fibrosisMedDRA version: 8.1Level: LLTClassification code 10011763Term: Cystic fibrosis lung

EUCTR2007-002912-24-DEBayer HealthCare AG16

Active, not recruiting

Phase 1

A study to investigate the safety, pharmacodynamics and pharmacokinetics of increasing doses of subcutaneously administered deuterated DMT (CYB004) in healthy subjects

CTIS2023-507409-32-00Cybin IRL Limited72

Recruiting

Phase 1

A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors-

JPRN-jRCT2080225128-6